NCT03713892

CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

Phase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of CKD-504 compared to placebo in healthy Korean and Caucasian adult subjects

Conditions

• Huntington Disease

Interventions

Type	Name	Description
DRUG	CKD-504	orally administered once with investigational drug assigned on 1d morning with 240 mL of water
DRUG	Placebo	orally administered

Timeline

• Start date: 2018-05-23
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2018-10-22
• Last updated: 2020-02-24

Locations

1 site across 1 country: South Korea